Options for Detecting Risk of Aminoglycoside-Induced Ototoxicity in Neonates—Reply

In Reply We are grateful to Mahmood and Leung for their interest in our article. They argue that there are more efficient ways to test for the MT-RNR1 m.1555A>G variant than the rapid point-of-care test (POCT) used in our study. They correctly state that m.1555A>G is subject to mitochondrial inheritance, and therefore knowing whether the mother was a carrier prior to delivery would negate the need for a rapid POCT. This biological assessment is sound, and testing every expectant mother for the variant would theoretically remove the need for rapid testing. However, this is neither cost-effective nor practicable.